Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib
– Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform to Accelerate Clinical Trial Timelines and Maximize Patient Outcomes-
-Volasertib is a PLK-1 inhibitor with therapeutic potential across a range of tumor types-
FOSTER CITY, Calif.–(BUSINESS WIRE)–Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer. Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in acute myeloid leukemia (AML) and other tumor types with significant unmet medical need.
Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development in this patient population.
Notable’s proprietary platform was built upon deep expertise across therapeutics, diagnostics, software, engineering, machine learning and automation. It quickly determines the response profile of individual patients prior to their cancer treatment, allowing for selective enrollment of predicted clinical responders into clinical trials.
“Volasertib represents an exciting milestone towards fulfilling Notable’s mission to deliver life-changing therapies precisely to those who will benefit, and leads the way in a new era of predictive precision medicine,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “We targeted and licensed volasertib because of its compelling performance on our Predictive Precision Medicine Platform and as an important addition to our growing clinical pipeline. We plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers, selectively enrolling patients who are predicted to respond.”
Dr. Bock added, “With the power of our high-fidelity prediction platform, volasertib represents just one of many compelling opportunities to match highly promising clinical candidates with the optimal patient population. We established our platform across a broad spectrum of drug classes and cancers, and are continuing to expand its capabilities across hematology and oncology. We are actively seeking in-licensing and partnership opportunities for those clinical-stage therapies that pass our platform’s rigorous demands. We are thrilled to be at the forefront in the field of predictive precision medicines and advance with the sense of urgency that patients with life-threatening conditions deserve.”
Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications. Oncoheroes will retain the license for development and commercialization of volasertib in pediatric indications. Financial terms of this deal are not disclosed.
Volasertib is an inhibitor of Polo-like-kinase 1 (PLK-1), an enzyme known to be involved in disease progression in a number of cancers. The compound was originally discovered and developed by Boehringer Ingelheim for the treatment of acute myeloid leukemia. Oncoheroes in-licensed volasertib from Boehringer Ingelheim and is developing volasertib for the treatment of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children and young adults. Volasertib was previously granted Orphan Drug Designation (ODD) for its use in treating pediatric rhabdomyosarcoma and other rare soft tissue sarcomas and received Rare Pediatric Disease Designation in 2020, by the U.S. Food and Drug Administration (FDA).
Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.
Notable’s proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.
Investors in Notable include B Capital Group, Builders VC, Lifeforce Capital, Founders Fund, First Round Capital, Y Combinator, several prominent angels and seed-stage funds, and Accelerate Brain Cancer Cure, a venture philanthropy firm founded by Steve Case. Notable’s offices are located in Foster City, Calif. Learn more at notablelabs.com and follow us @notablelabs.